| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 12.4 | 13.1 | 14.0 |
| Other income | 0.7 | 1.2 | 1.2 |
| Total income | 13.1 | 14.3 | 15.2 |
| Profit before exceptional items & tax | 0.9 | 1.9 | 1.3 |
| Exceptional items | 0.4 | 0.0 | 0.0 |
| Profit before tax | 0.5 | 1.9 | 1.3 |
| Net profit | 0.1 | 1.4 | 0.9 |
| Operating margin | 3.8% | 13.3% | 8.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -88.90% |
|---|---|
| Net profit, quarter on quarter | -92.90% |
| Revenue, year on year | -11.40% |
NSE results filing, NSE: NIDAN. Figures extracted from the filing.
Nidan Laboratories And Healthcare Ltd: key numbers
- Share price
- ₹13.00
- Market cap
- ₹18.07 Cr
- Revenue (annual)
- ₹25.54 Cr
- Net profit (annual)
- ₹1.51 Cr
- P/E (TTM)
- 12.0×Sector 53.1×
- Promoter holding
- 57.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nidan Laboratories And Healthcare Ltd
All →Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will hold its 26th Annual General Meeting on September 28, 2026. The company has submitted its Annual Report for FY 2025-26.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will convene its 26th Annual General Meeting on September 28, 2026. The board also approved book closure and e-voting schedules.
Nidan Laboratories And Healthcare Board Meeting Date
Nidan Laboratories and Healthcare Limited has scheduled a board meeting for August 20, 2026. The meeting agenda covers general business matters.
Nidan Laboratories And Healthcare Board Meeting Outcome
Nidan Laboratories approved FY26 audited financial results and re-appointed independent directors and statutory auditors. These board decisions ensure operational continuity and regulatory compliance.
Nidan Laboratories And Healthcare Management Change
Nidan Laboratories re-appointed Nilesh Bide and Abhinay Nerurkar as Independent Directors for five-year terms. These appointments ensure continued board stability and regulatory compliance.
- Execution
- 60 months
Nidan Laboratories And Healthcare Financial Results
Nidan Laboratories reported total income of ₹27.40 Crore for FY26. The board also approved the re-appointment of two independent directors and its statutory auditors.
- Value
- ₹27.40 Cr